ClinicalTrials.gg
CompletedNCT01877668OPAL BROADENUpdated Jul 6, 2017Results posted

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

A Phase 3 interventional study of Tofacitinib 5 mg BID and Tofacitinib 10 mg BID in Psoriatic Arthritis, sponsored by Pfizer. Completed at 123 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-06.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing tofacitinib in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. tofacitinib · Arthritis, Psoriatic.

Enrollment
3rd of 10
422 · median 237
Started
2014
with 1 other
Phase 3
7 of 10
1 open now
Registered
2nd of 10
by date
Lead sponsor
5 of 10
Pfizer

Among the 10 studies testing tofacitinib in Arthritis, Psoriatic, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 3, and was the 2nd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 10 studies testing tofacitinib in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing tofacitinib in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This is a 12-month study investigating the effectiveness and safety of tofactinib in treating the signs and symptoms of active psoriatic arthritis and improving physical function and preserving bone structure in patients with an inadequate response to a traditional, nonbiologic disease-modifying antirheumatic drug. Adalimumab is used as a comparator.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • psoriatic arthritis
  • radiographic changes
  • active comparator
  • tofacitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, aged >= 18 years at time of consent.
  • Have a diagnosis of Psoriatic arthritis (PsA) of >= 6 months
  • Meet the Classification Criteria of PsA (CASPAR) at time of screening
  • Must not have been adequately treated with a a traditional non-biologic disease modifying anti-rheumatic drug (DMARD).
  • Concurrent treatment with methotrexate, leflunomide, or sulfasalazine allowed and required
  • Must not have taken a biologic Tumour Necrosis Factor Inhibitor
  • Must have 3 or more swollen joints AND 3 or more tender joints
  • Must have active psoriasis skin lesions

Exclusion criteria

Exclusion Criteria:

  • Have non-plaque forms of psoriasis, eg erythrodermic, guttate or pustular, with the exception of nail psoriasis which is allowed
  • Pregnant or breast feeding, females of not using highly effective
  • Class III and IV congestive heart failure
  • History of or infusion reaction to biologic agents
  • Infection with , virus, virus, or other chronic infection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
422 participants (actual)

Study arms

  • Experimental
    Tofacitinib 5 mgBID x 12 months

    Drug: Tofacitinib 5 mg BID

  • Experimental
    Tofacitinib 10 mg BID x 12 months

    Drug: Tofacitinib 10 mg BID

  • Active comparator
    Adalimumab 40 mg q2 weeks x 12 months

    Drug: Adalimumab

  • Placebo comparator
    Placebo x3 months, then tofacitinib 5 mg BIDx 9 months

    Drug: Placebo

  • Placebo comparator
    Placebo x 3 months, then tofacitinib 10 mg BID x 9 months

    Drug: Placebo

Interventions

  • Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months

  • Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months

  • Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months

  • DrugPlacebo

    Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months

  • DrugPlacebo

    Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3

    ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire - disability index (HAQ-DI), and C-reactive protein (CRP).

    Time frame: At end of Month 3

  2. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

    The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.

    Time frame: From Baseline to Month 3

Secondary outcomes

  1. Change From Baseline in the Van Der Heijdel Modified Total Sharp Score (mTSS) for Psoriatic Arthritis

    Assessment of joint damage includes a joint erosion score (range 0-320) and a joint space narrowing (JSN) score (range 0-208). The mTSS is the sum of the erosion and JSN scores (range 0-528). A higher score indicates more severe disease status. If a component score is missing, the mTSS will be missing.

    Time frame: From Baseline to Month 12

  2. Percentage of Participants With Progressed Modified Total Sharp Score (mTSS) at Month 12

    Assessment of joint damage includes a joint erosion score (range 0-320) and a JSN score (range 0-208). The mTSS is the sum of the erosion and JSN scores (range 0-528). A higher score indicates more severe disease status. If a component score is missing, the mTSS will be missing. Progressor is defined as an increase in mTSS \>0.5 from baseline.

    Time frame: At Month 12

  3. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

    ACR50 was calculated as a ≥50% improvement from baseline in tender/painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.

    Time frame: At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

  4. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

    ACR70 was calculated as a ≥70% improvement from baseline in tender/painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. .

    Time frame: At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

  5. Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20) at Week 2 and Months 1, 2, 4, 6, 9, and 12

    ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.

    Time frame: At Week 2 and Months 1, 2, 4, 6, 9, and 12

  6. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

    The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.

    Time frame: From Baseline to Week 2 and Months 1, 2, 4, 6, 9, and 12

  7. Change From Baseline in American College of Rheumatology Response Criteria Components: C-reactive Protein Levels

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

    Time frame: From Baseline to end of Month 3

  8. Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Assessment of Arthritis Pain

    Participants assessed the severity of their arthritis pain using a 100-mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

    Time frame: From Baseline to end of Month 3

  9. Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Global Assessment of Arthritis

    Participant answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly).

    Time frame: From Baseline to end of Month 3

  10. Change From Baseline in American College of Rheumatology Response Criteria Components Score: Physician's Global Assessment of Arthritis

    The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor).

    Time frame: From Baseline to end of Month 3

  11. Change From Baseline in American College of Rheumatology Response Criteria Components Score: Swollen Joint Count

    Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.

    Time frame: From Baseline to end of Month 3

  12. Change From Baseline in American College of Rheumatology Response Criteria Components Score: Tender/Painful Joint Count

    Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.

    Time frame: From Baseline to end of Month 3

  13. Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

    The PsARC covers 4 measures: Tender/painful joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count.

    Time frame: At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

  14. Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response

    The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  15. Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response at Months 1, 3, 6, 9, and 12

    PASI determines psoriasis severity based on lesion severity \& percentage body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, \& scaling, evaluated separately for head \& neck, upper limbs, trunk, \& lower limbs \& rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis \& is assigned a score: 0=no involvement; 1=0-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. In each area, sum of severity rating scores is multiplied by the score representing the percentage of area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of numbers obtained for the 4 body areas is the PASI score \& can vary in increments of 0.1 \& range from 0.0 to 72.0, higher scores represent greater severity of psoriasis. PASI75 is defined as a 75% reduction from baseline in PASI.

    Time frame: At Months 1, 3, 6, 9, and 12

  16. Change From Baseline in Dactylitis Severity Score (DSS)

    Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=no tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a patient is 0-60. Higher score indicates greater degree of tenderness.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  17. Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index

    The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  18. Change From Baseline in the Leeds Enthesitis Index (LEI)

    Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for an total score of 0-6. Higher score indicates a greater number of sites that are affected by enthesitis.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  19. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2) Acute, Physical Component Summary Score

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represents better physical health status.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  20. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute, Mental Component Summary Score

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  21. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Physical Functioning Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represents better physical functioning.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  22. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Role-Physical Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represents better role-physical functioning.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  23. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Bodily Pain Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represents less bodily pain.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  24. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: General Health Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher general health domain score represents better general health perceptions.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  25. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Vitality Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher vitality domain score represents better vitality.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  26. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Social Functioning Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher social functioning domain score represents better social functioning.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  27. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Role-Emotional Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-emotional domain score represents better role-emotional functioning.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  28. Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Mental Health Domain

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher mental health domain score represents better mental health functioning.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  29. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  30. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-care

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  31. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  32. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  33. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  34. Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today

    The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 (worst imaginable health state) to 100 mm (best imaginable health state) visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher scores indicate a better health state, with a higher value representing better health status.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  35. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score

    FACIT-F is a 13-item questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0 to 52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  36. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score

    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  37. Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score

    FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

  38. Change From Baseline in Scores Evaluating Spondylitis Using the Bath Anklyosing Spondylitis Disease Activity Index (BASDAI)

    BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a visual analog scale of 0-100mm (0=none and 100=very severe) participants answer 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averages the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity.

    Time frame: From Baseline to Months 1, 3, 6, 9, and 12

07

Results

Posted Jul 6, 2017

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice Daily
Started1071041065253
Completed9696944443
Not completed11812810
Withdrew: Death00010
Withdrew: No longer met study criteria10100
Withdrew: Insufficient clinical response01220
Withdrew: Lost to follow-up02100
Withdrew: Withdrawal by subject20322
Withdrew: Other11113
Withdrew: Protocol violation11003
Withdrew: Adverse event related to study drug22221
Withdrew: Adverse event unrelated to study drug41201

Outcome measures

PrimaryPercentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3

ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire - disability index (HAQ-DI), and C-reactive protein (CRP).

Time frame:
At end of Month 3
Reported as:
Number · Percentage or participants
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3
Percentage or participantsTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 350.4760.5851.8933.33
Statistical analysis
  • Tofacitinib, 5 mg, Twice Daily vs Placebo · Large sample approximation · p = 0.0102 · Risk difference (rd): 17.13 · 95% CI 4.06 to 30.21Missing response (MR)=non-response (NR)
  • Tofacitinib, 10 mg, Twice Daily vs Placebo · Large sample approximation · p = <0.0001 · Risk difference (rd): 27.24 · 95% CI 14.22 to 40.26MR=NR
  • Adalimumab, 40 mg, Every 2 Weeks vs Placebo · Large sample approximation · p = 0.0055 · Risk difference (rd): 18.55 · 95% CI 5.45 to 31.66MR=NR
PrimaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.

Time frame:
From Baseline to Month 3
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score-0.3499 ± 0.04665-0.3998 ± 0.04716-0.3808 ± 0.04767-0.1802 ± 0.05031
Statistical analysis
  • Tofacitinib, 5 mg, Twice Daily vs Placebo · Mixed Models Analysis · p = 0.0062 · Mean difference (net): -0.1697 · 95% CI -0.2910 to -0.0483No imputation.
  • Tofacitinib, 10 mg, Twice Daily vs Placebo · Mixed Models Analysis · p = 0.0004 · Mean difference (net): -0.2196 · 95% CI -0.3411 to -0.0980No imputation.
  • Adalimumab, 40 mg, Every 2 Weeks vs Placebo · Mixed Models Analysis · p = 0.0012 · Mean difference (net): -0.2005 · 95% CI -0.3213 to -0.0797No imputation.
SecondaryChange From Baseline in the Van Der Heijdel Modified Total Sharp Score (mTSS) for Psoriatic Arthritis

Assessment of joint damage includes a joint erosion score (range 0-320) and a joint space narrowing (JSN) score (range 0-208). The mTSS is the sum of the erosion and JSN scores (range 0-528). A higher score indicates more severe disease status. If a component score is missing, the mTSS will be missing.

Time frame:
From Baseline to Month 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Van Der Heijdel Modified Total Sharp Score (mTSS) for Psoriatic Arthritis
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice Daily
Change From Baseline in the Van Der Heijdel Modified Total Sharp Score (mTSS) for Psoriatic Arthritis0.01 ± 0.067-0.01 ± 0.067-0.07 ± 0.0690.00 ± 0.0940.09 ± 0.099
SecondaryPercentage of Participants With Progressed Modified Total Sharp Score (mTSS) at Month 12

Assessment of joint damage includes a joint erosion score (range 0-320) and a JSN score (range 0-208). The mTSS is the sum of the erosion and JSN scores (range 0-528). A higher score indicates more severe disease status. If a component score is missing, the mTSS will be missing. Progressor is defined as an increase in mTSS \>0.5 from baseline.

Time frame:
At Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Progressed Modified Total Sharp Score (mTSS) at Month 12
Percentage of participantsTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice Daily
Percentage of Participants With Progressed Modified Total Sharp Score (mTSS) at Month 124.085.052.114.178.89
SecondaryPercentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

ACR50 was calculated as a ≥50% improvement from baseline in tender/painful and swollen joint counts and ≥50% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.

Time frame:
At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥50% (ACR50) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
Percentage of participantsTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Week 2 (n=7, 7, 5, NA, NA, 1)6.546.734.72NANA0.95
Month 1 (n=13, 20,12, NA, NA, 5)12.1519.2311.32NANA4.76
Month 2 (n=23, 34, 24, NA, NA, 8)21.5032.6922.64NANA7.62
Month 3 (n=30, 42, 35, NA, NA, 10)28.0440.3833.02NANA9.52
Month 4 (n=38, 39, 34, 11, 17, NA)35.5137.5032.0821.1532.08NA
Month 6 (n=41, 48, 45, 17, 14, NA)38.3246.1542.4532.6926.42NA
Month 9 (n=45, 48, 49, 22, 23, NA)42.0646.1546.2342.3143.40NA
Month 12 (n=48, 50, 43, 21, 19, NA)44.8648.0840.5740.3835.85NA
SecondaryPercentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

ACR70 was calculated as a ≥70% improvement from baseline in tender/painful and swollen joint counts and ≥70% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP. .

Time frame:
At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥70% (ACR70) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
Percentage of participantsTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Week 2 (n=0, 3, 1, NA, NA, 0)0.002.880.94NANA0.00
Month 1 (n=5, 8, 4, NA, NA, 1)4.677.693.77NANA0.95
Month 2 (n=10, 14, 13, NA, NA, 2)9.3513.4612.26NANA1.90
Month 3 (n=18, 15, 20, NA, NA, 5)16.8214.4218.87NANA4.76
Month 4 (n=24, 23, 21, 7, 8, NA)22.4322.1219.8113.4615.09NA
Month 6 (n=19, 33, 32, 10, 7, NA)17.7631.7330.1919.2313.21NA
Month 9 (n=21, 31, 30, 15, 12, NA)19.6329.8128.3028.8522.64NA
Month 12 (n=25, 32, 31, 12, 12, NA)23.3630.7729.2523.0822.64NA
SecondaryPercentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20) at Week 2 and Months 1, 2, 4, 6, 9, and 12

ACR20 was calculated as a ≥20% improvement from baseline in tender/painful and swollen joint counts and ≥20% improvement from baseline in 3 of the 5 remaining ACR core set measures: patient's global assessment of arthritis, physician's global assessment of arthritis, patient's assessment of arthritis pain, HAQ-DI, and CRP.

Time frame:
At Week 2 and Months 1, 2, 4, 6, 9, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20) at Week 2 and Months 1, 2, 4, 6, 9, and 12
Percentage of participantsTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Week 2 (n=24, 33, 23, NA, NA, 6)22.4331.7321.70NANA5.71
Month 1 (n=37, 50, 30, NA, NA, 11)34.5848.0828.30NANA10.48
Month 2 (n=47, 57, 62, NA, NA, 28)43.9354.8158.49NANA26.67
Month 4 (n=65, 60, 61, 27, 28, NA)60.7557.6957.5551.9252.83NA
Month 6 (n=63, 70, 68, 31, 30, NA)58.8867.3164.1559.6256.60NA
Month 9 (n=73, 76, 73, 35, 37, NA)68.2273.0868.8767.3169.81NA
Month 12 (n=73, 73, 64, 35, 31, NA)68.2270.1960.3867.3158.49NA
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

The HAQ-DI assesses the difficulty a participant has had in the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question, level of difficulty is scored from 0 to 3 with 0=no difficulty, 1=some difficulty, 2=much difficulty, and 3=unable to do. The score for each domain is the maximum (worst) score from the items/questions within the domain. Higher score indicates greater disability.

Time frame:
From Baseline to Week 2 and Months 1, 2, 4, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Week 2 (n=106, 102, 103, NA, NA, 102)-0.1842 ± 0.04131-0.2089 ± 0.04208-0.2129 ± 0.04246NA ± NANA ± NA-0.0837 ± 0.04549
Month 1 (n=105, 103, 104, NA, NA, 103)-0.2048 ± 0.04363-0.2676 ± 0.04426-0.3028 ± 0.04465NA ± NANA ± NA-0.1224 ± 0.04755
Month 2 (n=104, 104, 104, NA, NA, 102)-0.2713 ± 0.04626-0.4009 ± 0.04678-0.3736 ± 0.04719NA ± NANA ± NA-0.1682 ± 0.04998
Month 4 (n=102, 100, 102, 50, 50, NA)-0.4231 ± 0.04982-0.4407 ± 0.05039-0.3643 ± 0.05069-0.2850 ± 0.07075-0.3302 ± 0.07128NA ± NA
Month 6 (n=100, 100, 99, 48, 48, NA)-0.4471 ± 0.05136-0.4611 ± 0.05179-0.4259 ± 0.05227-0.3142 ± 0.07315-0.3841 ± 0.07369NA ± NA
Month 9 (n=99, 96, 96, 47, 45, NA)-0.5119 ± 0.05038-0.4847 ± 0.05096-0.4304 ± 0.05143-0.3843 ± 0.07185-0.4839 ± 0.07276NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)-0.5391 ± 0.05324-0.5104 ± 0.05365-0.4478 ± 0.05426-0.4104 ± 0.07646-0.4569 ± 0.07704NA ± NA
SecondaryChange From Baseline in American College of Rheumatology Response Criteria Components: C-reactive Protein Levels

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.

Time frame:
From Baseline to end of Month 3
Reported as:
Least squares mean · mg/L
Change From Baseline in American College of Rheumatology Response Criteria Components: C-reactive Protein Levels
mg/LTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo
Change From Baseline in American College of Rheumatology Response Criteria Components: C-reactive Protein Levels-5.5981 ± 0.80656-6.6004 ± 0.80822-7.8955 ± 0.82547-0.8643 ± 0.86304
SecondaryChange From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Assessment of Arthritis Pain

Participants assessed the severity of their arthritis pain using a 100-mm visual analog scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain.

Time frame:
From Baseline to end of Month 3
Reported as:
Least squares mean · mm
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Assessment of Arthritis Pain
mmTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Assessment of Arthritis Pain-21.49 ± 2.325-27.10 ± 2.342-21.87 ± 2.389-10.22 ± 2.499
SecondaryChange From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Global Assessment of Arthritis

Participant answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The participant's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very well) and 100 (very poorly).

Time frame:
From Baseline to end of Month 3
Reported as:
Least squares mean · mm
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Global Assessment of Arthritis
mmTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Patient's Global Assessment of Arthritis-20.08 ± 2.275-25.50 ± 2.291-21.47 ± 2.328-11.40 ± 2.439
SecondaryChange From Baseline in American College of Rheumatology Response Criteria Components Score: Physician's Global Assessment of Arthritis

The blinded investigator or qualified assessor assessed how the participant's overall arthritis appeared at the time of the visit. This was an evaluation based on the participant's disease signs, functional capacity and physical examination, and was independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS by placing a mark on the scale between 0 (very good) and 100 (very poor).

Time frame:
From Baseline to end of Month 3
Reported as:
Least squares mean · mm
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Physician's Global Assessment of Arthritis
mmTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Physician's Global Assessment of Arthritis-27.44 ± 1.998-33.74 ± 2.021-29.02 ± 2.043-22.26 ± 2.121
SecondaryChange From Baseline in American College of Rheumatology Response Criteria Components Score: Swollen Joint Count

Swollen joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty six (66) joints were assessed by a blinded assessor to determine the number of joints that were considered swelling.

Time frame:
From Baseline to end of Month 3
Reported as:
Least squares mean · Joints
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Swollen Joint Count
JointsTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Swollen Joint Count-6.5 ± 0.58-7.6 ± 0.58-6.5 ± 0.59-4.8 ± 0.62
SecondaryChange From Baseline in American College of Rheumatology Response Criteria Components Score: Tender/Painful Joint Count

Tender/painful joint counts are considered the most specific quantitative clinical measure used to assess the status of participants with inflammatory types of arthritis. Sixty eight (68) joints were assessed by a blinded assessor to determine the number of joints that were considered tender or painful.

Time frame:
From Baseline to end of Month 3
Reported as:
Least squares mean · Joints
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Tender/Painful Joint Count
JointsTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo
Change From Baseline in American College of Rheumatology Response Criteria Components Score: Tender/Painful Joint Count-8.7 ± 1.04-11.0 ± 1.05-7.6 ± 1.07-6.9 ± 1.10
SecondaryPercentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12

The PsARC covers 4 measures: Tender/painful joint count, swollen joint count, the Physician's Global Assessment of Arthritis, and the Patient's Global Assessment of Arthritis. The PsARC response is defined as improvement in 2 of 4 items, 1 of which must be joint pain or swelling, without worsening in any measure. Improvement criteria: ≥20% improvement in Physician's Global Assessment of Arthritis; ≥20% improvement in Patient's Global Assessment of Arthritis; ≥30% improvement in tender joint count; and ≥30% improvement in swollen joint count.

Time frame:
At Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting Psoriatic Arthritis Response Criteria (PsARC) at Week 2 and Months 1, 2, 3, 4, 6, 9, and 12
Percentage of participantsTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Week 2 (n=34, 42, 23, NA, NA, 10)31.7840.3821.70NANA9.52
Month 1 (n=45, 51, 43, NA, NA, 23)42.0649.0440.57NANA21.90
Month 2 (n=54, 69, 62, NA, NA, 36)50.4766.3558.49NANA34.29
Month 3 (n=55, 73, 65, NA, NA, 47)51.4070.1961.32NANA44.76
Month 4 (n=68, 68, 71, 32, 30, NA)63.5565.3866.9861.5456.60NA
Month 6 (n=61, 75, 71, 35, 35, NA)57.0172.1266.9867.3166.04NA
Month 9 (n=75, 73, 71, 36, 37, NA)70.0970.1966.9869.2369.81NA
Month 12 (n=69, 76, 69, 39, 33, NA)64.4973.0865.0975.0062.26NA
SecondaryChange From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response

The PGA-PsO is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are rated separately over the whole body according to a 5-point severity scale, scored as 0=none; 1, 2, 3, or 4=most severe. The severity rating scores are summed and the average taken; the total average is rounded to the nearest whole number score to determine a PGA-PsO score on a scale of 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Physician's Global Assessment of Psoriasis (PGA-PsO) Response
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=100, 96, 100, NA, NA, 99)-0.7 ± 0.07-0.8 ± 0.08-0.5 ± 0.08NA ± NANA ± NA-0.2 ± 0.08
Month 3 (n=98, 97, 98, NA, NA, 98)-1.0 ± 0.08-1.2 ± 0.08-1.0 ± 0.09NA ± NANA ± NA-0.4 ± 0.09
Month 6 (n=96, 94, 96, 46, 46, NA)-0.9 ± 0.09-1.3 ± 0.09-1.2 ± 0.09-0.7 ± 0.12-0.9 ± 0.13NA ± NA
Month 9 (n=95, 91, 94, 45, 44, NA)-1.0 ± 0.09-1.5 ± 0.09-1.2 ± 0.09-0.7 ± 0.12-1.3 ± 0.13NA ± NA
Month 12 (n=91, 90, 92, 41, 43, NA)-1.2 ± 0.09-1.5 ± 0.09-1.2 ± 0.09-0.9 ± 0.13-1.3 ± 0.13NA ± NA
SecondaryPercentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response at Months 1, 3, 6, 9, and 12

PASI determines psoriasis severity based on lesion severity \& percentage body surface area (BSA) affected. Lesion severity is assessed for erythema, induration, \& scaling, evaluated separately for head \& neck, upper limbs, trunk, \& lower limbs \& rated for each body area according to a 5 point scale: 0=no involvement; 1=slight; 2=moderate; 3=marked; 4=very marked. BSA involvement is the extent (%) of body area affected by psoriasis \& is assigned a score: 0=no involvement; 1=0-9%; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; 6=90-100%. In each area, sum of severity rating scores is multiplied by the score representing the percentage of area involved by psoriasis, multiplied by a weighting factor (head 0.1; upper limbs 0.2; trunk 0.3; lower limbs 0.4). The sum of numbers obtained for the 4 body areas is the PASI score \& can vary in increments of 0.1 \& range from 0.0 to 72.0, higher scores represent greater severity of psoriasis. PASI75 is defined as a 75% reduction from baseline in PASI.

Time frame:
At Months 1, 3, 6, 9, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response at Months 1, 3, 6, 9, and 12
Percentage of participantsTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=19, 19, 11, NA, NA, 4)23.17 ± 4.6627.14 ± 5.3214.29 ± 3.99NA ± NANA ± NA4.88 ± 2.38
Month 3 (n=35, 31, 30, NA, NA, 12)42.68 ± 5.4644.29 ± 5.9438.96 ± 5.56NA ± NANA ± NA14.63 ± 3.90
Month 6 (n=38, 42, 42, 12, 17, NA)46.34 ± 5.5160.00 ± 5.8654.55 ± 5.6728.57 ± 6.9742.50 ± 7.82NA ± NA
Month 9 (n=36, 48, 45, 14, 20, NA)43.90 ± 5.44868.57 ± 5.5558.44 ± 5.6233.33 ± 7.2750.00 ± 7.91NA ± NA
Month 12 (n=46, 47, 43, 15, 21, NA)56.10 ± 5.4867.14 ± 5.6155.84 ± 5.6635.71 ± 7.3952.50 ± 7.90NA ± NA
SecondaryChange From Baseline in Dactylitis Severity Score (DSS)

Dactylitis is characterized by swelling of the entire finger or toe. The DSS is a function of finger circumference and tenderness, assessed and summed across all dactylitic digits. The severity of dactylitis is scored on a scale of 0-3, where 0=no tenderness and 3=extreme tenderness in each digit of the hands and feet. The range of total dactylitis scores for a patient is 0-60. Higher score indicates greater degree of tenderness.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Dactylitis Severity Score (DSS)
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=58, 59, 56, NA, NA, 56)-1.8 ± 0.91-3.1 ± 0.87-2.1 ± 0.93NA ± NANA ± NA0.6 ± 1.02
Month 3 (n=58, 60 , 56, NA, NA, 55)-3.5 ± 0.95-5.5 ± 0.91-4.0 ± 0.97NA ± NANA ± NA-2.0 ± 1.06
Month 6 (n=58, 59, 55, 28, 25, NA)-5.2 ± 1.01-6.4 ± 0.99-5.4 ± 1.03-5.9 ± 1.45-5.2 ± 1.50NA ± NA
Month 9 (n=57, 59, 53, 27, 25, NA)-7.0 ± 0.60-7.2 ± 0.58-6.5 ± 0.63-5.3 ± 0.87-7.9 ± 0.89NA ± NA
Month 12 (n=54, 58, 52, 26, 24, NA)-7.4 ± 0.65-7.5 ± 0.62-6.1 ± 0.67-6.7 ± 0.93-7.7 ± 0.96NA ± NA
SecondaryChange From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index

The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. On examination, tenderness is recorded as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=79, 80, 80, NA, NA, 78)-0.83 ± 0.317-1.27 ± 0.321-0.95 ± 0.336NA ± NANA ± NA-0.58 ± 0.355
Month 3 (n=77, 79, 79, NA, NA, 78)-1.84 ± 0.363-2.41 ± 0.364-1.90 ± 0.375NA ± NANA ± NA-1.17 ± 0.393
Month 6 (n=76, 78, 76, 33, 39, NA)-2.4 ± 0.34-2.6 ± 0.34-2.3 ± 0.35-2.4 ± 0.50-2.5 ± 0.48NA ± NA
Month 9 (n=75, 75, 73, 34, 37, NA)-2.9 ± 0.31-2.6 ± 0.32-3.0 ± 0.33-2.8 ± 0.46-3.2 ± 0.44NA ± NA
Month 12 (n=72, 73, 72, 31, 37, NA)-3.2 ± 0.33-3.1 ± 0.33-2.8 ± 0.35-2.5 ± 0.49-3.2 ± 0.46NA ± NA
SecondaryChange From Baseline in the Leeds Enthesitis Index (LEI)

Enthesitis is inflammation in the tendon, ligament, and joint capsule fiber insertion into bone. The LEI assesses enthesitis in 6 sites. Tenderness is recorded as either present (1) or absent (0) for each of the 6 sites, for an total score of 0-6. Higher score indicates a greater number of sites that are affected by enthesitis.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Leeds Enthesitis Index (LEI)
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=74, 63, 75, NA, NA, 65)-0.41 ± 0.192-0.57 ± 0.213-0.42 ± 0.203NA ± NANA ± NA-0.26 ± 0.219
Month 3 (n=70, 63, 73, NA, NA, 63)-0.82 ± 0.221-1.46 ± 0.240-1.10 ± 0.228NA ± NANA ± NA-0.43 ± 0.246
Month 6 (n=72, 61, 71, 27, 31, NA)-1.3 ± 0.21-1.2 ± 0.23-1.3 ± 0.22-1.0 ± 0.32-1.3 ± 0.30NA ± NA
Month 9 (n=70, 58, 68, 27, 29, NA)-1.4 ± 0.20-1.3 ± 0.23-1.5 ± 0.21-1.4 ± 0.31-1.7 ± 0.30NA ± NA
Month 12 (n=67, 56, 67, 24, 29, NA)-1.7 ± 0.19-1.6 ± 0.21-1.6 ± 0.20-1.4 ± 0.30-1.9 ± 0.28NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2) Acute, Physical Component Summary Score

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a standard deviation (SD) of 10 points, and ranges from minus infinity to plus infinity. A higher PCS score represents better physical health status.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2) Acute, Physical Component Summary Score
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103,104, NA, NA, 103)3.39 ± 0.6384.66 ± 0.6454.00 ± 0.655NA ± NANA ± NA1.54 ± 0.700
Month 3 (n=102, 103,100, NA, NA, 102)5.51 ± 0.7335.69 ± 0.7356.23 ± 0.748NA ± NANA ± NA2.68 ± 0.785
Month 6 (n=100, 100, 98, 48, 48, NA)6.72 ± 0.7736.70 ± 0.7776.26 ± 0.7885.86 ± 1.1016.07 ± 1.112NA ± NA
Month 9 (n=99, 97, 95, 47, 46, NA)7.52 ± 0.7817.21 ± 0.7876.91 ± 0.7986.16 ± 1.1157.15 ± 1.130NA ± NA
Month 12 (n=96, 96, 94, 44, 43, NA)7.61 ± 0.8067.67 ± 0.8106.74 ± 0.8225.82 ± 1.1605.72 ± 1.177NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute, Mental Component Summary Score

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher MCS score represents better mental health status.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute, Mental Component Summary Score
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103,104,NA, NA, 103)4.12 ± 0.8413.63 ± 0.8492.13 ± 0.871NA ± NANA ± NA3.19 ± 0.917
Month 3 (n=102, 103,100, NA, NA, 102)4.35 ± 0.9094.20 ± 0.9093.13 ± 0.938NA ± NANA ± NA3.27 ± 0.976
Month 6 (n=100, 100, 98, 48, 48, NA)5.70 ± 0.9275.51 ± 0.9304.58 ± 0.9554.50 ± 1.3193.62 ± 1.331NA ± NA
Month 9 (n=99, 97, 95, 47, 46, NA)5.07 ± 0.9746.20 ± 0.9823.68 ± 1.0054.61 ± 1.3916.03 ± 1.409NA ± NA
Month 12 (n=96, 96, 94, 44, 43, NA)4.82 ± 1.0126.26 ± 1.0164.81 ± 1.0394.51 ± 1.4554.43 ± 1.474NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Physical Functioning Domain

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher physical functioning domain score represents better physical functioning.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Physical Functioning Domain
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103,104, NA, NA, 103)2.43 ± 0.7683.89 ± 0.7762.81 ± 0.787NA ± NANA ± NA1.10 ± 0.840
Month 3 (n=102, 103,101, NA, NA, 102)5.17 ± 0.8465.23 ± 0.8485.22 ± 0.862NA ± NANA ± NA2.06 ± 0.910
Month 6 (n=100, 100, 99, 48, 48, NA)7.02 ± 0.8976.15 ± 0.9006.36 ± 0.9125.22 ± 1.2765.22 ± 1.291NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)7.43 ± 0.9026.67 ± 0.9097.01 ± 0.9215.69 ± 1.2856.25 ± 1.306NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)7.67 ± 0.8997.11 ± 0.9036.81 ± 0.9176.49 ± 1.2924.77 ± 1.308NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Role-Physical Domain

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-physical domain score represents better role-physical functioning.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Role-Physical Domain
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103,104, NA, NA, 103)4.05 ± 0.7513.72 ± 0.7594.09 ± 0.770NA ± NANA ± NA1.98 ± 0.820
Month 3 (n=102, 103, 100, NA, NA, 102)4.45 ± 0.8014.79 ± 0.8035.21 ± 0.820NA ± NANA ± NA3.63 ± 0.862
Month 6 (n=100, 100, 99, 48, 48, NA)6.02 ± 0.8245.21 ± 0.8285.48 ± 0.8404.97 ± 1.1725.03 ± 1.185NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)6.24 ± 0.8536.56 ± 0.8615.79 ± 0.8724.68 ± 1.2176.70 ± 1.234NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)6.21 ± 0.8887.11 ± 0.8926.37 ± 0.9062.98 ± 1.2795.03 ± 1.291NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Bodily Pain Domain

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher bodily pain domain score represents less bodily pain.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Bodily Pain Domain
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103,104, NA, NA, 103)5.53 ± 0.7777.16 ± 0.7866.42 ± 0.802NA ± NANA ± NA3.44 ± 0.851
Month 3 (n=102, 103, 101, NA, NA, 102)7.75 ± 0.8388.05 ± 0.8407.52 ± 0.859NA ± NANA ± NA3.77 ± 0.903
Month 6 (n=100, 100, 99, 48, 48, NA)7.76 ± 0.98510.65 ± 0.9897.76 ± 1.0048.55 ± 1.4058.98 ± 1.425NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)9.03 ± 0.95310.13 ± 0.9608.59 ± 0.9778.46 ± 1.36210.81 ± 1.389NA ± NA
Month 12 (n=96, 96, 94, 44, 43, NA)9.15 ± 0.96111.38 ± 0.9659.18 ± 0.9848.59 ± 1.3848.61 ± 1.413NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: General Health Domain

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher general health domain score represents better general health perceptions.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: General Health Domain
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103,104, NA, NA, 103)3.29 ± 0.6103.87 ± 0.6161.96 ± 0.625NA ± NANA ± NA2.15 ± 0.666
Month 3 (n=102, 103,101, NA, NA, 102 )4.09 ± 0.7003.95 ± 0.7014.73 ± 0.713NA ± NANA ± NA2.64 ± 0.748
Month 6 (n=100, 100, 99, 48, 48, NA)5.96 ± 0.7204.12 ± 0.7224.81 ± 0.7334.39 ± 1.0223.92 ± 1.033NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)5.93 ± 0.7735.18 ± 0.7784.09 ± 0.7884.72 ± 1.1024.85 ± 1.117NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)5.70 ± 0.8114.63 ± 0.8154.21 ± 0.8254.50 ± 1.1644.12 ± 1.175NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Vitality Domain

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher vitality domain score represents better vitality.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Vitality Domain
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103,104, NA, NA, 103)3.64 ± 0.8024.59 ± 0.8062.42 ± 0.826NA ± NANA ± NA2.16 ± 0.877
Month 3 (n=102, 103, 101, NA, NA, 102)5.50 ± 0.8895.90 ± 0.8874.93 ± 0.909NA ± NANA ± NA3.05 ± 0.954
Month 6 (n=100, 100, 99, 48, 48, NA)6.81 ± 0.9697.41 ± 0.9705.05 ± 0.9895.34 ± 1.3784.62 ± 1.394NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)6.09 ± 1.0177.82 ± 1.0235.27 ± 1.0416.61 ± 1.4516.39 ± 1.472NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)7.01 ± 1.0227.02 ± 1.0245.12 ± 1.0435.62 ± 1.4655.15 ± 1.481NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Social Functioning Domain

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher social functioning domain score represents better social functioning.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Social Functioning Domain
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103,104, NA, NA, 103)4.51 ± 0.8274.46 ± 0.8383.34 ± 0.852NA ± NANA ± NA2.96 ± 0.901
Month 3 (n=102, 103, 101, NA, NA, 102)5.95 ± 0.8975.22 ± 0.8985.26 ± 0.918NA ± NANA ± NA3.63 ± 0.961
Month 6 (n=100, 100, 99, 48, 48, NA)6.97 ± 0.9557.08 ± 0.9597.10 ± 0.9755.44 ± 1.3626.05 ± 1.373NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)7.66 ± 0.9477.74 ± 0.9575.69 ± 0.9725.95 ± 1.3558.93 ± 1.373NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)6.13 ± 0.9898.42 ± 0.9956.32 ± 1.0126.19 ± 1.4276.41 ± 1.445NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Role-Emotional Domain

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher role-emotional domain score represents better role-emotional functioning.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Role-Emotional Domain
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103,104, NA, NA, 103)4.77 ± 0.9603.87 ± 0.9712.93 ± 0.991NA ± NANA ± NA4.52 ± 1.042
Month 3 (n=102, 103, 100, NA, NA, 102)4.21 ± 1.0104.82 ± 1.0113.35 ± 1.040NA ± NANA ± NA3.68 ± 1.083
Month 6 (n=100, 100, 98, 48, 48, NA)5.67 ± 1.0244.68 ± 1.0274.77 ± 1.0516.34 ± 1.4584.56 ± 1.473NA ± NA
Month 9 (n=99, 97, 95, 47, 46, NA)5.13 ± 1.0216.13 ± 1.0304.87 ± 1.0525.89 ± 1.4566.52 ± 1.478NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)5.15 ± 1.0486.73 ± 1.0536.03 ± 1.0754.77 ± 1.5094.94 ± 1.525NA ± NA
SecondaryChange From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Mental Health Domain

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. An additional item measures health transition. The 8 health domains are aggregated into two summary scores known as the PCS score and the MCS score. Norm-based domain scores, PCS and MCS scores are used in the analyses; each of which has a population mean of 50 with a SD of 10 points, and ranges from minus infinity to plus infinity. A higher mental health domain score represents better mental health functioning.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Short-Form-36 Health Survey Version 2 (SF-36v2), Acute Components: Mental Health Domain
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103, 104, NA, NA, 103)3.32 ± 0.8673.87 ± 0.8742.79 ± 0.895NA ± NANA ± NA1.57 ± 0.952
Month 3 (n=102, 103, 101, NA, NA, 102)4.45 ± 0.9344.23 ± 0.9323.95 ± 0.956NA ± NANA ± NA2.62 ± 1.009
Month 6 (n=100, 100, 99, 48, 48, NA)6.11 ± 0.9516.38 ± 0.9535.35 ± 0.9743.70 ± 1.3543.41 ± 1.372NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)5.79 ± 1.0226.43 ± 1.0284.62 ± 1.0483.57 ± 1.4615.45 ± 1.483NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)5.86 ± 1.0196.58 ± 1.0225.86 ± 1.0444.72 ± 1.4674.48 ± 1.483NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Mobility
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103, 104, NA, NA, 103)-0.07 ± 0.042-0.19 ± 0.043-0.15 ± 0.043NA ± NANA ± NA-0.10 ± 0.046
Month 3 (n=101, 103, 101, NA, NA, 102)-0.28 ± 0.047-0.27 ± 0.047-0.29 ± 0.048NA ± NANA ± NA-0.11 ± 0.050
Month 6 (n=100, 100, 99, 48, 48, NA)-0.3 ± 0.05-0.3 ± 0.05-0.2 ± 0.05-0.3 ± 0.07-0.2 ± 0.07NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)-0.3 ± 0.05-0.3 ± 0.05-0.3 ± 0.05-0.3 ± 0.07-0.3 ± 0.07NA ± NA
Month 12 (n=96, 96, 94, 44,44, NA)-0.3 ± 0.05-0.3 ± 0.05-0.3 ± 0.05-0.4 ± 0.07-0.3 ± 0.07NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-care

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Self-care
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 102, 104, NA, NA, 103)-0.11 ± 0.046-0.16 ± 0.047-0.16 ± 0.047NA ± NANA ± NA-0.09 ± 0.050
Month 3 (n=101, 102, 101, NA, NA, 102)-0.19 ± 0.047-0.11 ± 0.047-0.18 ± 0.048NA ± NANA ± NA-0.12 ± 0.051
Month 6 (n=100, 99, 99, 48, 48, NA)-0.2 ± 0.04-0.3 ± 0.05-0.2 ± 0.05-0.2 ± 0.06-0.3 ± 0.06NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)-0.2 ± 0.05-0.2 ± 0.05-0.3 ± 0.05-0.2 ± 0.06-0.3 ± 0.07NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)-0.2 ± 0.05-0.3 ± 0.05-0.3 ± 0.05-0.3 ± 0.07-0.2 ± 0.07NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Usual Activities
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 102, 104, NA, NA, 103)-0.17 ± 0.043-0.19 ± 0.043-0.21 ± 0.044NA ± NANA ± NA-0.06 ± 0.047
Month 3 (n=101, 102, 101, NA, NA, 102)-0.24 ± 0.049-0.29 ± 0.049-0.29 ± 0.049NA ± NANA ± NA-0.17 ± 0.052
Month 6 (n=100, 99, 99, 48, 47, NA)-0.3 ± 0.05-0.3 ± 0.05-0.4 ± 0.05-0.3 ± 0.07-0.3 ± 0.07NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)-0.3 ± 0.05-0.4 ± 0.05-0.4 ± 0.05-0.3 ± 0.07-0.4 ± 0.07NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)-0.3 ± 0.05-0.4 ± 0.05-0.4 ± 0.05-0.3 ± 0.07-0.3 ± 0.07NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Pain/Discomfort
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103, 104, NA, NA, 103)-0.14 ± 0.039-0.25 ± 0.040-0.19 ± 0.040NA ± NANA ± NA-0.08 ± 0.043
Month 3 (n=101, 103, 101, NA, NA, 102)-0.25 ± 0.044-0.27 ± 0.044-0.28 ± 0.045NA ± NANA ± NA-0.08 ± 0.047
Month 6 (n=100, 100, 99, 48, 48, NA)-0.3 ± 0.05-0.4 ± 0.05-0.3 ± 0.05-0.3 ± 0.07-0.4 ± 0.07NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)-0.3 ± 0.05-0.3 ± 0.05-0.3 ± 0.05-0.4 ± 0.07-0.4 ± 0.07NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)-0.3 ± 0.05-0.4 ± 0.05-0.3 ± 0.05-0.2 ± 0.07-0.3 ± 0.07NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 to 100 mm visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state, with a higher value representing better health status.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Anxiety/Depression
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103, 104, NA, NA, 103)-0.25 ± 0.051-0.22 ± 0.052-0.27 ± 0.053NA ± NANA ± NA-0.21 ± 0.056
Month 3 (n=101, 103, 100, NA, NA, 102)-0.25 ± 0.055-0.17 ± 0.055-0.32 ± 0.056NA ± NANA ± NA-0.21 ± 0.059
Month 6 (n=100, 100, 99, 48, 48, NA)-0.3 ± 0.05-0.3 ± 0.05-0.3 ± 0.05-0.3 ± 0.08-0.2 ± 0.08NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)-0.3 ± 0.05-0.4 ± 0.05-0.4 ± 0.06-0.2 ± 0.08-0.3 ± 0.08NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)-0.3 ± 0.05-0.4 ± 0.05-0.4 ± 0.06-0.2 ± 0.08-0.3 ± 0.08NA ± NA
SecondaryChange From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today

The EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take 1 of 3 responses. The responses record 3 levels of severity (no problems \[1\], some or moderate problems \[2\], or extreme problems \[3\]) within a particular EQ-5D dimension. Standard vertical 0 (worst imaginable health state) to 100 mm (best imaginable health state) visual analogue scale (similar to a thermometer) for recording an individual's rating for their current health-related quality of life state; higher scores indicate a better health state, with a higher value representing better health status.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · mm
Change From Baseline in Score on EuroQol-5 Dimension Health State Profile (EQ-5D) and Change in Patient's Self-rated Health on a Vertical Visual Analogue Scale (VAS) Recorded on the EQ-5D Questionnaire (EQ-VAS): Patient's Health State Today
mmTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103, 104, NA, NA, 103)10.75 ± 1.85910.81 ± 1.88010.27 ± 1.917NA ± NANA ± NA6.59 ± 2.027
Month 3 (n=101, 103, 101, NA, NA, 101)14.00 ± 2.10015.83 ± 2.09213.10 ± 2.138NA ± NANA ± NA6.37 ± 2.242
Month 6 (n=100, 100, 99, 48, 48, NA)19.5 ± 2.0815.7 ± 2.0915.5 ± 2.1214.7 ± 2.9716.6 ± 3.00NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)19.2 ± 2.2115.9 ± 2.2318.2 ± 2.2612.8 ± 3.1621.5 ± 3.21NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)20.7 ± 2.0919.8 ± 2.0916.5 ± 2.1416.0 ± 3.0219.8 ± 3.05NA ± NA
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score

FACIT-F is a 13-item questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0 to 52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better fatigue status.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Total Score
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103, 104, NA, NA, 103)5.2 ± 0.774.4 ± 0.784.2 ± 0.79NA ± NANA ± NA2.7 ± 0.84
Month 3 (102, 102, 101, NA, NA, 102)7.0 ± 0.856.0 ± 0.856.0 ± 0.87NA ± NANA ± NA3.3 ± 0.91
Month 6 (n=100, 100, 99,48, 48, NA)7.9 ± 0.898.0 ± 0.896.5 ± 0.916.5 ± 1.267.2 ± 1.28NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)7.9 ± 0.927.4 ± 0.926.5 ± 0.945.5 ± 1.318.4 ± 1.33NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)8.5 ± 0.958.4 ± 0.956.9 ± 0.975.7 ± 1.367.6 ± 1.38NA ± NA
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score

FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue experience.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Experience Domain Score
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103, 104, NA, NA, 103)2.4 ± 0.352.1 ± 0.352.1 ± 0.36NA ± NANA ± NA1.2 ± 0.38
Month 3 (n=102, 102, 101, NA, NA, 102)3.3 ± 0.382.8 ± 0.382.9 ± 0.39NA ± NANA ± NA1.6 ± 0.41
Month 6 (n=100, 100, 99,48, 48, NA)3.6 ± 0.403.3 ± 0.403.2 ± 0.413.0 ± 0.573.3 ± 0.58NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)3.6 ± 0.423.3 ± 0.423.3 ± 0.432.7 ± 0.593.9 ± 0.60NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)3.9 ± 0.443.7 ± 0.443.2 ± 0.452.7 ± 0.633.4 ± 0.63NA ± NA
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score

FACIT-F is a 13-item questionnaire, with each item score ranging from 0 to 4. Three endpoints are derived: change in FACIT-F total score, change in FACIT-F experience domain score, and change in FACIT-F impact domain score. FACIT-F total score (range 0-52) is calculated by summing the 13 items. FACIT-F experience domain score (range 0-20) is calculated by summing 5 items : I feel fatigued, I feel weak all over, I feel listless ("washed out"), I feel tired, and I have energy, while FACIT-F impact domain score (range 0-32) is calculated by summing the remaining 8 items. All responses are added with equal weight to obtain the total score. Higher scores represent better (less) fatigue impact on daily functioning.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scores: Impact Domain Score
Units on a scaleTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=105, 103, 104, NA, NA, 103)2.9 ± 0.472.3 ± 0.482.1 ± 0.49NA ± NANA ± NA1.5 ± 0.52
Month 3 (n=102, 102, 101, NA, NA, 102)3.8 ± 0.523.2 ± 0.523.2 ± 0.53NA ± NANA ± NA1.8 ± 0.56
Month 6 (n=100, 100, 99,48, 48, NA)4.3 ± 0.534.7 ± 0.533.4 ± 0.543.5 ± 0.754.0 ± 0.76NA ± NA
Month 9 (n=99, 97, 96, 47, 46, NA)4.3 ± 0.554.1 ± 0.553.3 ± 0.562.8 ± 0.784.6 ± 0.80NA ± NA
Month 12 (n=96, 96, 94, 44, 44, NA)4.6 ± 0.574.7 ± 0.573.7 ± 0.582.9 ± 0.824.3 ± 0.82NA ± NA
SecondaryChange From Baseline in Scores Evaluating Spondylitis Using the Bath Anklyosing Spondylitis Disease Activity Index (BASDAI)

BASDAI is a validated self-assessment tool used to determine disease activity in participants with ankylosing spondylitis. Utilizing a visual analog scale of 0-100mm (0=none and 100=very severe) participants answer 6 questions measuring discomfort, pain, and fatigue. The final BASDAI score averages the individual assessments for a final score ranging 0-10cm, with higher scores representing more severe ankylosing spondylitis disease activity.

Time frame:
From Baseline to Months 1, 3, 6, 9, and 12
Reported as:
Least squares mean · cm
Change From Baseline in Scores Evaluating Spondylitis Using the Bath Anklyosing Spondylitis Disease Activity Index (BASDAI)
cmTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyPlacebo
Month 1 (n=24, 21, 10, NA, NA, 22)-1.23 ± 0.537-1.60 ± 0.508-2.30 ± 0.673NA ± NANA ± NA-1.27 ± 0.581
Month 3 (n=24, 21, 10, NA, NA, 22)-1.83 ± 0.579-2.78 ± 0.559-2.93 ± 0.753NA ± NANA ± NA-1.60 ± 0.624
Month 6 (n=23, 21, 10, 9, 11, NA)-2.24 ± 0.580-2.35 ± 0.560-3.58 ± 0.758-2.85 ± 0.778-3.31 ± 0.744NA ± NA
Month 9 (n=23, 20, 10, 9, 9, NA)-2.06 ± 0.575-2.71 ± 0.5582.66 ± 0.747-3.00 ± 0.770-3.35 ± 0.761NA ± NA
Month 12 (n=23, 19, 10, 9, 9, NA)-2.50 ± 0.594-3.30 ± 0.587-2.42 ± 0.779-2.31 ± 0.808-2.67 ± 0.806NA ± NA

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib, 5 mg, Twice Daily—8/107 (7.5%)31/107 (29%)
Tofacitinib, 10 mg, Twice Daily—4/104 (3.8%)43/104 (41.3%)
Adalimumab, 40 mg, Every 2 Weeks—9/106 (8.5%)43/106 (40.6%)
Placebo/Tofacitinib, 5 mg, Twice Daily—3/52 (5.8%)15/52 (28.8%)
Placebo/Tofacitinib, 10 mg, Twice Daily—4/53 (7.5%)22/53 (41.5%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice Daily
Cardiac arrestCardiac disorders0/1070/1040/1061/520/53
AppendicitisInfections and infestations0/1070/1040/1061/520/53
PneumoniaInfections and infestations0/1070/1040/1061/520/53
Abdominal herniaGastrointestinal disorders0/1070/1040/1060/521/53
DiverticulumGastrointestinal disorders0/1070/1040/1060/521/53
SpondylolisthesisMusculoskeletal and connective tissue disorders0/1070/1040/1060/521/53
NephropathyRenal and urinary disorders0/1070/1040/1060/521/53
Uterine polypReproductive system and breast disorders0/1070/1040/1060/521/53
Deep vein thrombosisVascular disorders0/1070/1040/1060/521/53
InfluenzaInfections and infestations0/1071/1040/1060/520/53
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice Daily
NasopharyngitisInfections and infestations8/10712/10411/1064/524/53
Upper respiratory tract infectionInfections and infestations10/10711/1048/1065/525/53
HeadacheNervous system disorders5/10711/1047/1062/524/53
Blood creatine phosphokinase increasedInvestigations5/1075/1043/1061/525/53
Urinary tract infectionInfections and infestations2/1074/1044/1061/524/53
Alanine aminotransferase increasedInvestigations3/1073/1048/1063/521/53
PharyngitisInfections and infestations5/1076/1047/1060/523/53
Aspartate aminotransferase increasedInvestigations0/1071/1047/1061/521/53
Spinal painMusculoskeletal and connective tissue disorders2/1071/1043/1063/520/53
Abdominal painGastrointestinal disorders1/1071/1042/1060/523/53

Baseline characteristics

All participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)Tofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyTotal
Mean49.4 ± 12.646.9 ± 12.447.4 ± 11.346.1 ± 10.449.3 ± 13.847.9 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib, 5 mg, Twice DailyTofacitinib, 10 mg, Twice DailyAdalimumab, 40 mg, Every 2 WeeksPlacebo/Tofacitinib, 5 mg, Twice DailyPlacebo/Tofacitinib, 10 mg, Twice DailyTotal
Female5762502828225
Male5042562425197
08

Study locations

123 sites
  • Rheumatology Associates, PC
    Birmingham, Alabama 35205, United States
  • Rheumatology Associates of North Alabama, PC
    Huntsville, Alabama 35801, United States
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Glendale, Arizona 85306, United States
  • Medvin Clinical Research
    Covina, California 91723, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Advances In Medicine (X-Rays)
    Rancho Mirage, California 92270, United States
  • San Diego Arthritis Medical Clinic
    San Diego, California 92108, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • Arthritis Center, Inc.
    Palm Harbor, Florida 34684, United States
  • Klein & Associates, M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • St. Paul Rheumatology, PA
    Eagan, Minnesota 55121, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Dartmouth-Hitchcock Medical Center (DHMC)
    Lebanon, New Hampshire 03756, United States
  • Paramount Medical Research & Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Low Country Rheumatology, PA
    Charleston, South Carolina 29406, United States
  • Pioneer Research Solutions, Inc.
    Houston, Texas 77008, United States
  • Drug Shipment/Storage: Huntsman Cancer Hospital at the University of Utah
    Salt Lake City, Utah 84112, United States
  • University of Utah Hospital & Clinics
    Salt Lake City, Utah 84132, United States
  • Dynacare Laboratories (Specimen processing for shipment)
    Seattle, Washington 98122, United States
  • Investigational Drug Service Pharmacy, Swedish Medical Center.
    Seattle, Washington 98122, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98122, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • Rheumatology Research Unit
    Maroochydore, Queensland 4558, Australia
  • Pacific Private Clinic
    Southport, Queensland 4215, Australia
  • Monash Health, Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Pharmacy Clinical Trials
    Clayton, Victoria 3168, Australia
  • St. Vincent's Hospital (Melbourne)
    Fitzroy, Victoria 3065, Australia
  • Emeritus Research Pty Ltd
    Malvern East, Victoria 3145, Australia
  • Hopital Erasme - Clinique Universitaire de Bruxelles
    Brussels, 1070, Belgium
  • University Hospital Leuven, Department of Rheumatology
    Leuven, 3000, Belgium
  • UMHAT "Dr. G. Stranski" EAD
    Pleven, 5800, Bulgaria
  • MHAT"Plovdiv" AD
    Plovdiv, 4000, Bulgaria
  • MHAT "Kaspela" EOOD
    Plovdiv, 4002, Bulgaria
  • UMHAT "Sv. Ivan Rilski" EAD
    Sofia, 1612, Bulgaria
  • MC "New rehabilitation center" EOOD, Rheumatology Cabinet
    Stara Zagora, 6003, Bulgaria
  • Rheumatology Research Associates
    Edmonton, Alberta T5M 0H4, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • West Island Rheumatology Research Associates
    Pointe-Claire, Quebec H9R 3J1, Canada
  • Revmacentrum MUDr. Mostera, s.r.o.
    Brno, Czech Republic 615 00, Czechia
  • MEDIGAP, s.r.o. (radiology only)
    Praha 1 - Nove Mesto, Czech Republic 110 00, Czechia
  • Revmatologicky Ustav - Lekarna (pharmacy only)
    Praha 2, Czech Republic 128 50, Czechia
  • Revmatologicka ambulance
    Praha 4, Czech Republic 140 00, Czechia
  • Lekarna Na Lidicke (Pharmacy only)
    Brno, 602 00, Czechia
  • X-MEDICA s.r.o (radiology only)
    Brno, 61300, Czechia
  • Revmatologie s.r.o.
    Brno, 638 00, Czechia
  • Stavovska s.r.o. (pharmacy only)
    Brno, 63800, Czechia
  • Vesalion s.r.o.
    Ostrava, 70200, Czechia
  • MEDIGAP, s.r.o
    Praha 1- Nove Mesto, 110 00, Czechia
  • Revmatologicky ustav - Lekarna
    Praha 2, 128 50, Czechia
  • Revmatologicky ustav
    Praha 2, 128 50, Czechia
  • Medical Plus s.r.o. Lekarna Hradebni s. r.o
    Uherske Hradiste, 68601, Czechia
  • Centre Hospitalier Sud-Francilien - Secretariat de Rhumatologie
    Corbeil Essonnes cedex, 91106, France
  • Charite Universitaetsmedizin Berlin
    Berlin, 10117, Germany
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany
  • Rheumapraxis Steglitz
    Berlin, 12161, Germany
  • University Hospital of Cologne
    Koeln, 50937, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • Revita Reumatologiai Rendelo
    Budapest, 1027, Hungary
  • Qualiclinic Kft.
    Budapest, 1036, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont,Reumatologiai osztaly
    Budapest, 1062, Hungary
  • Csolnoky Ferenc Korhaz, Radiologiai Osztaly X-Ray Only
    Veszprem, 8200, Hungary
  • Csolnoky Ferenc Korhaz, Reumatologiai Osztaly
    Veszprem, 8200, Hungary
  • Centro Integral en Reumatologia SA de CV
    Guadalajara, Jalisco 44160, Mexico
  • Centro de Investigacion de Tratamientos Innovadores de Sinaloa, S.C.
    Culiacan, Sinaloa 80000, Mexico
  • Laboratorios de Analisis Clinicos CEMSI
    Culiacan, Sinaloa 80000, Mexico
  • Sanatorio CEMSI Chapultepec (For Emergencies Only)
    Culiacan, Sinaloa 80040, Mexico
  • Hospital General de Culiacán Dr. Bernardo J. Gastélum
    Culiacan, Sinaloa 80230, Mexico
  • Instituto Medico Panamericano, S.A. de C.V. (For Emergencies Only)
    Merida, Yucatan 97000, Mexico
  • Unidad Reumatologica Las Americas, S.C.P.
    Merida, Yucatan 97000, Mexico
  • Centro de Investigacion Clinica Pensiones
    Merida, Yucatan 97070, Mexico
  • Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan
    Merida, Yucatan 97130, Mexico
  • Hospital Star Medica Merida (For Emergencies Only)
    Merida, Yucatan 97133, Mexico
  • HOSPITAL STAR MEDICA S.A DE C.V- (emergencies only)
    Merida, Yucatan 97133, Mexico
  • Investigacion y Biomedicina de Chihuahua SC
    Chihuahua, 31000, Mexico
  • Cliditer, S. A. de C. V
    Mexico City, 06700, Mexico
  • Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Chirurgiczna dla Dzieci "PriamaMed" Sp.P.,"
    Bialystok, 15-002, Poland
  • ZDROWIE OSTEO-MEDIC s.c. L. i A. Racewicz, A. i J. Supronik
    Bialystok, 15-351, Poland
  • ClinicMed Badurski i wspolnicy Spolka Jawna
    Bialystok, 15-879, Poland
  • Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy,
    Bydgoszcz, 85-168, Poland
  • Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka Partnerska
    Elblag, 82-300, Poland
  • Centrum Radiologii for X-Ray only
    Elblag, 82-300, Poland
  • NZOZ Centrum Reumatologiczne Indywidualna Specjalistyczna Praktyka Lekarska Lek. Med. Barbara Bazela
    Elblag, 82-300, Poland
  • Przychodnia Specjalistyczna Lekarskiej Spoldzielni Pracy "Medica"
    Grodzisk Mazowiecki, 05-825, Poland
  • Zespol Poradni Specjalistycznych Reumed Filia Onyksowa
    Lublin, 20-582, Poland
  • NZOZ Lecznica MAK-MED S.C.
    Nadarzyn, 05-830, Poland
  • Prywatna Praktyka Lekarska Prof. UM dr hab. Pawel Hrycaj
    Poznan, 61-397, Poland
  • NZOZ Nasz Lekarz Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna w Toruniu
    Torun, 87-100, Poland
  • Medica Pro Familia Sp. z o.o. S.K.A.
    Warsaw, 01-868, Poland
  • Rheuma Medicus Zaklad Opieki Zdrowotnej
    Warszawa, 02-118, Poland
  • Reumatika Centrum Reumatologii
    Warszawa, 02-691, Poland
  • Klinika Ambroziak Estederm Sp. z o.o. ,S.K.A
    Warszawa, 02-758, Poland
  • Synexus Polska Sp. z o.o. Oddz. we Wroclawiu
    Wroclaw, 50-088, Poland
  • Regional State Budgetary Healthcare Institution of Karelia Republic
    Petrozavodsk, Karelia Republic 185019, Russian Federation
  • State Budgetary Institution of Healthcare of Moscow City Clinical Hospital
    Moscow, 119049, Russian Federation
  • OOO City Neurological Centre "Sibneiromed"
    Novosibirsk, 630091, Russian Federation
  • Limited Liability Company Consultative Diagnostic Rheumatology Center "Healthy Joints"
    Novosibirsk, 630099, Russian Federation
  • State Institution of Healthcare "Regional Clinical Hospital"
    Saratov, 410053, Russian Federation
  • State Budget Educational Institution of Highest Professional Education
    Tomsk, 634050, Russian Federation

Showing the first 100 of 123 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • de Vlam K, Mease PJ, Bushmakin AG, Fleischmann R, Ogdie A, Azevedo VF, Merola JF, Woolcott J, Cappelleri JC, Fallon L, Taylor PC. Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis. Rheumatol Ther. 2022 Oct;9(5):1451-1464. doi: 10.1007/s40744-022-00482-5. Epub 2022 Sep 8. PubMed 36076054 ↗
  • Orbai AM, Mease PJ, Helliwell PS, FitzGerald O, Fleishaker DL, Mundayat R, Young P. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies. BMC Rheumatol. 2022 Sep 1;6(1):68. doi: 10.1186/s41927-022-00298-4. PubMed 36045453 ↗
  • Taylor PC, Bushmakin AG, Cappelleri JC, Young P, Germino R, Merola JF, Yosipovitch G. Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. J Dermatolog Treat. 2022 Aug;33(5):2614-2620. doi: 10.1080/09546634.2022.2060924. Epub 2022 Apr 11. PubMed 35385361 ↗
  • Gladman DD, Coates LC, Wu J, Fallon L, Bacci ED, Cappelleri JC, Bushmakin AG, Helliwell PS. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Res Ther. 2022 Feb 9;24(1):40. doi: 10.1186/s13075-022-02721-0. PubMed 35139908 ↗
  • Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17. PubMed 34921355 ↗
  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6. PubMed 34870800 ↗
  • Kivitz AJ, FitzGerald O, Nash P, Pang S, Azevedo VF, Wang C, Takiya L. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. Clin Rheumatol. 2022 Feb;41(2):499-511. doi: 10.1007/s10067-021-05894-2. Epub 2021 Sep 12. PubMed 34510295 ↗
  • de Vlam K, Ogdie A, Bushmakin AG, Cappelleri JC, Fleischmann R, Taylor PC, Azevedo V, Fallon L, Woolcott J, Mease PJ. Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. RMD Open. 2021 Jul;7(2):e001609. doi: 10.1136/rmdopen-2021-001609. PubMed 34226183 ↗
  • Coates LC, Bushmakin AG, FitzGerald O, Gladman DD, Fallon L, Cappelleri JC, Hsu MA, Helliwell PS. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. Arthritis Res Ther. 2021 Mar 26;23(1):94. doi: 10.1186/s13075-021-02474-2. PubMed 33766074 ↗
  • Ritchlin CT, Giles JT, Ogdie A, Gomez-Reino JJ, Helliwell P, Young P, Wang C, Wu J, Romero AB, Woolcott J, Stockert L. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. ACR Open Rheumatol. 2020 Oct;2(10):543-554. doi: 10.1002/acr2.11166. Epub 2020 Sep 10. PubMed 32910531 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Burmester GR, Curtis JR, Yun H, FitzGerald O, Winthrop KL, Azevedo VF, Rigby WFC, Kanik KS, Wang C, Biswas P, Jones T, Palmetto N, Hendrikx T, Menon S, Rojo R. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Saf. 2020 Apr;43(4):379-392. doi: 10.1007/s40264-020-00904-9. PubMed 32006348 ↗
  • Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. Arthritis Care Res (Hoboken). 2019 Oct;71(10):1387-1395. doi: 10.1002/acr.23930. PubMed 31112005 ↗
  • Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019 May 20;3(1):30. doi: 10.1186/s41687-019-0115-4. PubMed 31111255 ↗
  • van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L. Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. J Rheumatol. 2019 Sep;46(9):1089-1096. doi: 10.3899/jrheum.180971. Epub 2019 Mar 1. PubMed 30824647 ↗
  • Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu MA. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019 Jan 11;5(1):e000806. doi: 10.1136/rmdopen-2018-000806. eCollection 2019. PubMed 30713721 ↗
  • Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis. J Patient Rep Outcomes. 2019 Jan 24;3(1):5. doi: 10.1186/s41687-019-0094-5. PubMed 30680661 ↗
  • Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, Wang C, Wu J, Menon S, Hendrikx T, Ports WC. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018 Dec;5(2):567-582. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9. PubMed 30414064 ↗
  • Helliwell P, Coates LC, FitzGerald O, Nash P, Soriano ER, Elaine Husni M, Hsu MA, Kanik KS, Hendrikx T, Wu J, Kudlacz E. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018 Oct 29;20(1):242. doi: 10.1186/s13075-018-1739-0. PubMed 30373651 ↗
  • Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieslak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975. PubMed 29045212 ↗

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Dec 2015, 22 months.

Results were first posted in Jul 2017, 1 year 6 months after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 22 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2013
First posted
Jun 14, 2013
StartActual
Jan 20, 2014
Primary completionActual
Dec 18, 2015
CompletionActual
Dec 18, 2015
Results first posted
Jul 6, 2017
Last update
Jul 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01877668
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 14, 2013
Start date
Jan 20, 2014
Primary completion
Dec 18, 2015
Completion
Dec 18, 2015
Results posted
Jul 6, 2017
Last update
Jul 6, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion